Vardenafil
- Generic Name
- Vardenafil
- Brand Names
- Levitra, Staxyn
- Drug Type
- Small Molecule
- Chemical Formula
- C23H32N6O4S
- CAS Number
- 224785-90-4
- Unique Ingredient Identifier
- UCE6F4125H
- Background
Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction. During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing ...
- Indication
Vardenafil is indicated for the treatment of erectile dysfunction.
- Associated Conditions
- Erectile Dysfunction
- Associated Therapies
- -
Vardenafil and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV)
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- University of Florence
- Target Recruit Count
- 30
- Registration Number
- NCT02450188
- Locations
- 🇮🇹
Ambulatori Medicina della Sessualità e Andrologia, Florence, Italy
Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis
- Conditions
- Interventions
- Drug: VardenafilProcedure: HVPG (Hepatic venous pressure measurement) baselineProcedure: HVPG (Hepatic venous pressure measurement) day 7Drug: Placebo intake once dailyBehavioral: IIEF 5 (International Index of Erectile Function) questionaire baselineBehavioral: IIEF 5 (International Index of Erectile Function) questionnaire at study phase end
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 30
- Registration Number
- NCT02344823
- Locations
- 🇦🇹
Dept. of Internal Medicine III, Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT02279992
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Diabetes & Vardenafil
- Conditions
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Azienda USL Modena
- Target Recruit Count
- 54
- Registration Number
- NCT02219646
- Locations
- 🇮🇹
Unit of Endocrinology Azienda USL, Modena, Italy
Improvement of Myocardial Blood Flow by PhosphoDiesterase 5 Inhibition in Coronary Artery Disease
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- Medical University of Vienna
- Registration Number
- NCT01406535
- Locations
- 🇦🇹
Rudolf Berger, MD, Vienna, Austria
Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome
- First Posted Date
- 2011-02-08
- Last Posted Date
- 2011-02-08
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 57
- Registration Number
- NCT01291199
- Locations
- 🇩🇪
University of Cologne - Heart Center, Cologne, NRW, Germany
The Safety of Vardenafil in Patients Undergoing Cardiac Surgery
- First Posted Date
- 2010-12-15
- Last Posted Date
- 2011-11-04
- Lead Sponsor
- McGuire Research Institute
- Target Recruit Count
- 10
- Registration Number
- NCT01260285
- Locations
- 🇺🇸
McGuire VAMC, Richmond, Virginia, United States
Clinical Proof-of-concept Study for the Combination BAY60-4552 / Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 140
- Registration Number
- NCT01168817
Correlation Study of Vascular Parameters in Hypertensive Men With Erectile Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2011-04-18
- Lead Sponsor
- Hospital Universitario Pedro Ernesto
- Target Recruit Count
- 100
- Registration Number
- NCT01084187
- Locations
- 🇧🇷
Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil
Does a Nasal Instillation of Vardenafil Normalize the Nasal Potential Difference in Cystic Fibrosis Patients?
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2019-02-25
- Target Recruit Count
- 5
- Registration Number
- NCT01002534
- Locations
- 🇧🇪
Cliniques universitaires St. Luc, Brussels, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.